Kidney Cancer

Dr. Michael Staehler highlighted nutrition’s role in kidney cancer, noting that diet, stress management, and lifestyle can impact outcomes and well-being.

The FDA has granted fast track designation to ITM-94 as a diagnostic agent for the detection of the most common type of kidney cancer.

A real-world study found TKIs were the most common therapy for adults with metastatic renal cell carcinoma after prior immune checkpoint inhibitor use.

A study at IKCS finds higher BMI after kidney cancer diagnosis improves survival, while significant weight loss predicts poorer outcomes.

American Indian and Alaskan Native individuals face some of the highest kidney cancer burdens in the United States.

Patients with advanced renal cell carcinoma whose disease has progressed on first-line therapies may benefit from the combination of Fruzaqla and Tyvyt.

Dr. Ravi Munver discusses how minimally invasive techniques allow patients to preserve kidney function and practical guidance for navigating treatment.

Remote monitoring has been found to be associated with improved postsurgical recovery for patients with cancer.

As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, kidney and other cancers.

This guide on stage 2 kidney cancer covers key info, treatments and what to expect, helping you prepare for informed discussions with your care team.

Molecular testing helps distinguish kidney cancer subtypes, ensuring patients get accurate diagnoses and treatment plans, avoiding unnecessary surgery.

Dr. Ravi Munver sat down for an interview with CURE to discuss progress in kidney cancer care.

I reflect on how my family and friends showed love in different ways during the early days of my chronic cancer diagnosis.

Researchers have created a novel immunotherapy for metastatic kidney cancer that could provide a new treatment option for patients with limited options.

Early-stage kidney cancer is limited to the kidney, usually under seven centimeters and often has a very good prognosis when treated promptly.

Kristen Dahlgren of the Cancer Vaccine Coalition spoke with CURE about why she remains hopeful for the future or cancer vaccines.

It is important to expand clinical trial access for patients with kidney cancer in order to ensure a representative study population.

Dr. Wenxin (Vincent) Xu discussed the benefit of using biomarkers to more precisely guide treatment for patients with renal cell carcinoma.

TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.

Six-time survivor Staci Kirk founded the Stiletto Boss Foundation to provide community, support and practical help for women of color beyond treatment.

A dual cancer diagnosis rewired how I live, love, and show up in the world — with presence, purpose, and unapologetic passion.

Fotivda preserved quality-of-life scores in kidney cancer, with better outcomes in second-line use and no added benefit from combining with Opdivo.

PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.